Manigaba et al. HCA Healthcare Journal of Medicine (2020) 1:COVID-19
https://doi.org/10.36518/2689-0216.1164

Case Report
Remdesivir-Warfarin Interaction: A Case Report
Kayihura Manigaba, PharmD, BCIDP,1 Josh Hawks, PharmD,1 Marie Kima, MD1

Abstract

Author affiliations are listed
at the end of this article.
Correspondence to:

Description

A greater than 65-year-old Caucasian woman receiving long-term anticoagulation with
warfarin for atrial fibrillation experienced a sudden rise in an international normalized ratio
(INR) after she was started on remdesivir for management of 2019 Novel Coronavirus
(COVID-19). Patient INR was maintained within the target therapeutic range of 2–3 with a
warfarin dose of 11 mg/week before starting remdesivir. After 2 days of remdesivir therapy,
the patient’s INR increased significantly and remained elevated during the 5 day course of
remdesivir therapy. Patient required an interruption of her warfarin therapy for 7 days, and
her INR did not return to the targeted therapeutic INR range of 2–3 until day 5 from the last
dose of remdesivir, despite no warfarin administration. A comprehensive PubMed/MEDLINE
search did not find published literature documenting interaction between warfarin and
remdesivir. We describe the first case report, to our knowledge, documenting a potential
drug interaction between warfarin and remdesivir. The authors found that there is a probable interaction between warfarin and remdesivir when applying the Adverse Drug Reaction
Probability Scale, Naranjo Scale. To reduce the risk of bleeding associated with excessive
anticoagulation, clinicians should closely monitor INR, and adjust the warfarin dose accordingly when patients are receiving remdesivir and warfarin concomitantly.
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Introduction

Remdesivir (formerly GS-5734) is a monophosphoramidate nucleoside analogue prodrug that
has shown broad-spectrum activity against
several coronaviruses including SARS-CoV-2,
a virus responsible for causing COVID-19.1 The
U.S. Food and Drug Administration (FDA)
issued an Emergency Use Authorization (EUA)
on May 1st, 2020 to allow emergency use of
remdesivir for treatment of hospitalized patients with severe COVID-19.2-3 There is currently a lack of in vivo data regarding remdesivir
drug interactions. In vitro data have shown
that remdesivir is an inhibitor of CYP3A4, and
a weak inhibitor of CYP1A2, CYP2C9, CYP2C19 and CYP2D6.4 As a prodrug, remdesivir
is rapidly converted to its active nucleoside
triphosphate form of GS-443902 and other
metabolites.4 The metabolism of remdesivir’s
metabolites has not been studied and data

regarding their interaction with other drugs is
lacking. Warfarin, a vitamin K antagonist, is a
commonly used anticoagulant for prophylaxis
and treatment of venous thrombosis, pulmonary embolism and thromboembolic complications associated with atrial fibrillation and/
or cardiac valve replacement.5 Warfarin is often
used to reduce the risk of death, recurrent
myocardial infarction and thromboembolic
events such as stroke or systemic embolization
after myocardial infarction.5 Warfarin drug interactions are mainly due to its hepatic metabolism through the cytochrome P450 system by
CYP2C9, CYP1A2 and CYP3A4.6 Although several drug interactions with warfarin are well described in the literature,7 there is a lack of data
regarding interaction between remdesivir and
warfarin. We describe the first case report, to
our knowledge, documenting a probable drug
interaction between remdesivir and warfarin.
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Case Presentation

A greater than 65-year-old Caucasian woman
was admitted at North Florida Regional Medical Center due to shortness of breath with
productive cough. Her relevant medical history
included atrial fibrillation, hypertension, and
chronic obstructive pulmonary disease (COPD)
requiring 4 liters of home oxygen therapy. Her
routine medications consisted of warfarin 11
mg/week with stable INR (2 mg oral [PO] on
Sunday, Monday, Wednesday and Friday, and
1 mg PO on Tuesday, Thursday and Saturday),
ipratropium bromide 17 mcg/act 2 puff inhaled
four times a day, fluticasone propionate 50
mcg/act twice daily as needed for nasal congestion, potassium chloride 20 meq PO daily,
furosemide 40 mg PO daily, levothyroxine 150
mcg PO daily, cyanocobalamin 1,000 mcg PO
daily, cholecalciferol 1,000 units PO daily and
simvastatin 40 mg PO at bedtime. The vital
signs on admission were Tmax of 37.1°C, blood
pressure 141/65 mm Hg, pulse 77 beats per
minute, respiratory rate 18 breaths per minute
and oxygen saturation of 100% on 10 liters of
oxygen via nasal cannula. The chest X-ray on
admission showed right lower lobe airspace
disease concerning for pneumonia. In addition

to the continuation of home medications, the
patient was started on ampicillin/sulbactam
1.5 gm IV every 8 hours and doxycycline 100 mg
PO every 12 hours for a 5 day course of therapy.
A COVID-19 test was collected on admission
and the result came back positive. The patient
was then started on hydroxychloroquine 400
mg PO every 12 hours for 2 doses, then 400 mg
PO every 24 hours for 3 days until patient was
switched to remdesivir when it became available under the EUA. Throughout the course
of her hospitalization, the INR was stable
until the start of remdesivir. (Table 1) Despite
significant reduction in warfarin dose, the INR
remained elevated until the patient finished
her treatment course with remdesivir and the
INR slowly stabilized again. Other liver function
tests remained stable and within normal limits
throughout the administration of remdesivir.
(Table 2)

Discussion

Remdesivir is a novel antiviral currently being
used in clinical practice for treatment of hospitalized patients with COVID-19. Remdesivir’s
mechanism of action is through inhibition of
SARS-COV-2 RNA-dependent RNA polymeras-

Table 1. Summary of the Patient’s Anticoagulation Management.
Day
INR (Goal 2-3) Warfarin Dose
Comments

386

Admission 2.3 (admission
(day 1)
baseline)

1 mg

Patient started on ampicillin/sulbactam and
doxycycline.

Day 2

2.3

2 mg

Hydroxychloroquine started.

Day 3

2.4

2 mg

Day 4

-

1 mg

Remdesivir 200 mg x1 loading dose started.
Hydroxychloroquine stopped.

Day 5

2.5

2 mg

Ampicillin/sulbactam and doxycycline stopped.
Remdesivir 100 mg IV daily ordered.

Day 6

3.4

hold

Day 7

3.8

hold

Day 8

4.2

hold

Day 9

4.6

hold

Day 10

4.1

hold

Day 11

3.8

hold

Day 12

3.2

hold

Day 13

2.4

1 mg

Last dose of remdesivir taken.
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Table 2. Liver Function Tests.
Day
Aspartate
Alanine
transamitransaminase (AST)
nase (ALT)
(units/L)
(Units/L)
Ref. 15-37
Ref. 13-56

Total
bilirubin
(mg/dl) Ref.
0.2-1

Direct
bilirubin
(mg/dl) Ref.
0- 0.2

Admission
(day 1)

13

9

0.4

0.1

Day 3

15

8

0.5

0.1

Day 6

14

9

0.6

0.2

Day 7

13

8

0.9

0.2

Comments

1 day prior to starting
remdesivir therapy.

Ref. = Reference range
es (RdRps) by incorporating its active nucleoside triphosphate, GS-443902, into the nascent
RNA chains.4 In addition to its active metabolites, remdesivir is rapidly converted to other
metabolites, mostly GS-704277 and the nucleoside analog GS-441524, once inside the cell.4
In vitro studies have shown that remdesivir is
an inhibitor of CYP3A4, and a weak inhibitor
of CYP1A2, CYP2C9, CYP2C19 and CYP2D6.4
The impact of remdesivir’s metabolites on the
cytochrome P450 system is unknown.
Warfarin is a commonly used medication in
clinical practice for patients requiring longterm anticoagulation. Warfarin acts by inhibiting the synthesis of vitamin K-dependent
clotting factors and the anticoagulant proteins
C and S. Warfarin exists as a racemic mixture of R-warfarin and S-warfarin isomers.
The S-isomer is 5 times more potent than the
R-isomer and is metabolized primarily by CYP2C9, whereas the R-isomer is metabolized by
CYP1A2 and CYP3A4 isoenzymes.6,7 Drugs that
inhibit CYP2C9, CYP1A2 and/or CYP3A4 can increase INR by increasing exposure to warfarin.6
The extent of remdesivir and its metabolites’
inhibition of the hepatic cytochrome P450
isoenzymes that metabolize warfarin is not
characterized in clinical practice. A comprehensive PubMed/MEDLINE search found no
documentation in the literature of warfarin and
remdesivir interaction. We report the first case
to our knowledge of a potential drug interaction between remdesivir and warfarin.
This case report describes a patient who had
a stable INR within the therapeutic range of

2–3 while taking a warfarin dose of 11 mg/week
prior to admission. The INR remained stable for
the first 5 days of hospitalization, then suddenly increased on the third day of remdesivir
therapy. The patient completed a 5-day course
of both ampicillin/sulbactam and doxycycline
with stable INR results without modification to
the patient’s home warfarin regimen. The only
change that took place before the noted INR
elevation was the start of remdesivir 2 days prior. The INR remained elevated for the duration
of remdesivir therapy, then began declining
upon completion of remdesivir treatment. The
INR did not return to the targeted therapeutic
range of 2–3 until 5 days after the last dose of
remdesivir. All other liver function tests remained within normal limits during the course
of remdesivir therapy. The calculated Naranjo
scale probability score was 6, suggesting that
the noted INR increase was secondary to a
probable drug interaction between warfarin
and remdesivir. (Table 3) The likely explanation
of the INR elevation in this patient is decreased
clearance of warfarin due to its interaction with
remdesivir and/or remdesivir’s metabolites
through the cytochrome P450 system.

Conclusion

Remdesivir is currently used widely for treatment of COVID-19 patients due to its documented clinical benefits of shortening the time
to recovery.9 The spectrum of remdesivir drug
interaction in clinical practice is not well characterized. We report the first case, to our knowledge, documenting a probable drug interaction
between warfarin and remdesivir. This case
report describes a patient who experienced a
significant rise in INR 2 days after remdesivir
387
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Table 3. Adverse Drug Reaction Probability Scale, Naranjo Scale: remdesivir-warfarin interaction.
Adverse Drug Reaction Probability Scale (Yes, No, Do Not Know)
Score
1. Are there previous conclusive reports on this reaction? (+1,0,0)

0

2. Did the adverse event appear after the suspected drug was administered? (+2,-1,0)

2

3. Did the adverse event improve when the drug was discontinued or a specific antagonist was administered? (+1,0,0)

1

4. Did the adverse event reappear when the drug was readministered? (+2,-1,0)

0

5. Are there alternative causes that could on their own have caused the reaction?
(-1,+2,0)

2

6. Did the reaction reappear when a placebo was given? (-1,+1,0)

0

7. Was the drug detected in blood or other fluids in concentrations known to be toxic?
(+1,0,0)

0

8. Was the reaction more severe when the dose was increased or less severe when the
dose was decreased? (+1,0,0)

0

9. Did the patient have a similar reaction to the same or similar drugs in any previous
exposure? (+1,0,0)

0

10. Was the adverse event confirmed by any objective evidence? (+1,0,0)

1
Total score

6

Total score ≤ 0: Doubtful; Total score 1 to 4: possible; Total score 5 to 8: probable; Total score ≥9: definite

therapy initiation, which required an interruption of warfarin therapy for 7 days. Clinicians
should closely monitor INR in patients who are
on warfarin and remdesivir concomitantly, and
adjust the warfarin dose accordingly.
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